Management of Skin Toxicities from EGFR Inhibitor Therapies

The information on the site is not country-specific, and may contain information that is outside the approved indications in the country in which you are located.

This site contains information and education for healthcare professionals and patients. Information presented in the native language within each country's website is governed by laws and regulations of that particular country, and therefore is intended for healthcare professionals in that country only.

Healthcare Professionals Patients

This section, for Healthcare Professionals, contains information, treatment algorithms and educational materials for healthcare professionals (HCPs) relating to the management of dermatological toxicities in patients treated with antibodies and small-molecule inhibitors directed towards the epidermal growth factor receptor (EGFR).

Access now

By pursuing, you confirm that you have read and understood the disclaimer.

This section, for Patients and Caregivers, provides you with information about skin problems that may occur when being treated against cancer with anti-EGFR drugs, such as Erbitux® (cetuximab), Iressa® (gefitinib), Tarceva® (erlotinib)Tyverb® (lapatinib), Vectibix® (panitumumab). When being treated, you are likely to have some skin problems. Usually these are mild but sometimes they can be more severe, especially if not treated quickly and correctly.

The information provided on this website will help you to minimise the impact of these skin reactions on your daily life. You will find guidance on what you can do, what you should avoid doing, when you should contact your doctor or nurse, and other practical tips.

Access now

By pursuing, you confirm that you have read and understood the disclaimer.

Content last updated in 2009.